Diamyd Medical AB to Include Children and Accelerate Patient Recruitment in U.S. Phase III Study With the Diamyd(r) Diabetes Vaccine
STOCKHOLM, Sweden, Aug. 27, 2009 (GLOBE NEWSWIRE) -- Diamyd Medical reported today that from September 1, children from 10 years of age with type 1 diabetes will be included in the company's U.S. Phase III study of the Diamyd(r) diabetes vaccine. The company is also trebling the number of clinics and is investing in expanded recruitment activities in the U.S.